Skip to content

Geron GERN AFS Securities

AFS Securities at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$54M+575%
Biogen logo
BiogenBIIB
$454.7M-32.0%
GRAIL, Inc. logo
GRAIL, Inc.GRAL
$820.38M+22.0%
Incyte logo
IncyteINCY
Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's AFS securities?
Geron (GERN) reported AFS securities of $270.19M in Q1 2026.
How has Geron's AFS securities changed year-over-year?
Geron's AFS securities decreased by 27.4% year-over-year, from $371.93M to $270.19M.
What is the long-term trend for Geron's AFS securities?
Over 4 years (2020 to 2025), Geron's AFS securities has grown at a 50.1% compound annual growth rate (CAGR), from $63.39M to $321.65M.
What does AFS securities mean?
Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.